Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy

• Shiwani Randhawa,
• Trilok Chand Saini,
• Manik Bathla,
• Rahul Bhardwaj,
• Rubina Dhiman and
• Amitabha Acharya

Beilstein J. Nanotechnol. 2025, 16, 561–580, doi:10.3762/bjnano.16.44

• ) enhance imaging sensitivity because of their distinct electrical or photoluminescent properties. For treatment, NPs can serve as drug carriers, improving delivery across the BBB and reducing side effects. Their large surface area allows for controlled drug release and targeted therapy, enhancing treatment

Radiosensitizing properties of dual-functionalized carbon nanostructures loaded with temozolomide

• Radmila Milenkovska,
• Nikola Geskovski,
• Dushko Shalabalija,
• Ljubica Mihailova,
• Petre Makreski,
• Dushko Lukarski,
• Igor Stojkovski,
• Maja Simonoska Crcarevska and
• Kristina Mladenovska

Beilstein J. Nanotechnol. 2025, 16, 229–251, doi:10.3762/bjnano.16.18

• ]. These findings are supported by several publications in which CNs were evaluated as potential drug carriers or inherent drugs for brain targeting and (synergistic) treatment of Alzheimer disease [20], Parkinson disease [21], and brain tumors [22][23][24][25], and as agents for the detection of brain

Probing the potential of rare earth elements in the development of new anticancer drugs: single molecule studies

• Josiane A. D. Batista,
• Rayane M. de Oliveira,
• Carlos H. M. Lima,
• Milton L. Lana Júnior,
• Virgílio C. dos Anjos,
• Maria J. V. Bell and
• Márcio S. Rocha

Beilstein J. Nanotechnol. 2025, 16, 187–194, doi:10.3762/bjnano.16.15

• side effects related to these therapies. Actually, both aspects depend on the development of new drugs and/or drug carriers that can improve the selectivity of these anticancer agents to reach their specific targets inside tumor cells [3][4][5]. Although commonly used in a number of technological

• , depending on the concentration used, two of the rare earths (erbium and neodymium) tested also present the ability to compact/condense DNA, which opens the door for other types of applications such as gene therapies and the design of drug carriers themselves. To achieve such results, we performed single

Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy

• Naths Grazia Sukubo,
• Paolo Bigini and
• Annalisa Morelli

Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10

• examines strategies that position macrophages as direct biological targets of NPs, aiming to modulate their activity as a therapeutic intervention for various pathological conditions, rather than merely using them as biomimetic drug carriers. 5.1 Targeted drug delivery to macrophages As described

Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals

• Selin Akpinar Adscheid,
• Akif E. Türeli,
• Nazende Günday-Türeli and
• Marc Schneider

Beilstein J. Nanotechnol. 2024, 15, 1400–1414, doi:10.3762/bjnano.15.113

• provide significant tailorable release properties to the encapsulated drugs. N2B delivery applications present increased efficacy and safety of the drugs in contrast to application of free drugs [63]. The physicochemical characteristics of the DDSs are important in determining the success of drug carriers

• the low drug loading capacity and drug expulsion during storage because of an increased crystallization tendency [102]. Researchers developed a second generation of lipid-based drug carriers called nanostructured lipid carriers (NLCs). Unlike the SLNs, the core structure of the NLCs is composed of

Unveiling the potential of alginate-based nanomaterials in sensing technology and smart delivery applications

• Shakhzodjon Uzokboev,
• Khojimukhammad Akhmadbekov,
• Ra’no Nuritdinova,
• Salah M. Tawfik and
• Yong-Ill Lee

Beilstein J. Nanotechnol. 2024, 15, 1077–1104, doi:10.3762/bjnano.15.88

• as drug carriers. Since then, tremendous progress has been achieved in the design, manufacture, and characterization of nanoparticle-based DDSs. The use of alginate in drug delivery goes back to the 1980s, when researchers first investigated its ability to encapsulate pharmaceuticals. Over time

Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• schistosomiasis due to their characteristics as drug carriers [10], metal nanoparticles usually present intrinsic action even when not loaded with drugs. Works with other parasites suggest that metallic nanoparticles may affect enzyme activity necessary to the physiology and production of the tegument [26

Elasticity, an often-overseen parameter in the development of nanoscale drug delivery systems

• Agnes-Valencia Weiss and
• Marc Schneider

Beilstein J. Nanotechnol. 2023, 14, 1149–1156, doi:10.3762/bjnano.14.95

• properties of drug carriers. Keywords: atomic force microscopy; drug delivery; elasticity; mechanical properties; nanomedicine; nanoparticles; stiffness measurement; tissue/body distribution; Introduction Drug delivery systems are developed with the aim to transport a given drug to the site of action

• surface modification, leading to a prolonged pulmonary retention of dexamethasone-loaded nanoparticulate drug carriers for the treatment of acute pulmonary inflammation [39]. This is in accordance with a study from Zheng et al. where crosslinked insulin-loaded hydrogel zwitterionic nanoparticles with

Recognition mechanisms of hemoglobin particles by monocytes – CD163 may just be one

• Jonathan-Gabriel Nimz,
• Pichayut Rerkshanandana,
• Chiraphat Kloypan,
• Ulrich Kalus,
• Saranya Chaiwaree,
• Axel Pruß,
• Radostina Georgieva,
• Yu Xiong and
• Hans Bäumler

Beilstein J. Nanotechnol. 2023, 14, 1028–1040, doi:10.3762/bjnano.14.85

• when using HbMPs as oxygen carriers [34]. In addition to transporting oxygen, HbMPs can also be used as drug carriers. However, in a pharmacokinetic study with HbMPs, accumulation of the particles in the sinusoids of the liver, where the Kupffer cells are located, was observed [35]. The mechanisms of

Polymer nanoparticles from low-energy nanoemulsions for biomedical applications

• Santiago Grijalvo and
• Carlos Rodriguez-Abreu

Beilstein J. Nanotechnol. 2023, 14, 339–350, doi:10.3762/bjnano.14.29

• research on the fabrication of polymer nanoparticles from low-energy nanoemulsions, focusing on phase inversion composition. We particularly emphasize their biomedical applications as drug carriers. 2 Nanoemulsions Nanoemulsions are constituted by nanoscale droplets (20–200 nm) dispersed in a continuous

Gelatin nanoparticles with tunable mechanical properties: effect of crosslinking time and loading

• Agnes-Valencia Weiss,
• Daniel Schorr,
• Julia K. Metz,
• Metin Yildirim,
• Saeed Ahmad Khan and
• Marc Schneider

Beilstein J. Nanotechnol. 2022, 13, 778–787, doi:10.3762/bjnano.13.68

• . Keywords: atomic force microscopy; drug delivery; elasticity; gelatin nanoparticles; Young’s modulus; Introduction Developing nanoparticulate drug carriers for various diseases and application routes requires establishing controllable systems, matching the needs of the respective application to achieve

• studies dealing with mechanical properties of nanoparticulate drug carriers determines the elasticity of bulk film material instead of that of the particles themselves [3]. Lack of appropriate equipment and training for measurements under physiological conditions might be the reasons. Alsharif et al

Detection and imaging of Hg(II) in vivo using glutathione-functionalized gold nanoparticles

• Gufeng Li,
• Shaoqing Li,
• Rui Wang,
• Min Yang,
• Lizhu Zhang,
• Yanli Zhang,
• Wenrong Yang and
• Hongbin Wang

Beilstein J. Nanotechnol. 2022, 13, 549–559, doi:10.3762/bjnano.13.46

• the fluorescent “ON” form. Keywords: cell imaging; fluorescence probes; glutathione; gold nanoparticles; mercury ions; rhodamine 6G derivatives; Introduction Metal nanoparticles have been widely used in the development and construction of sensor systems and drug carriers due to their excellent

Engineered titania nanomaterials in advanced clinical applications

• Padmavati Sahare,
• Paulina Govea Alvarez,
• Juan Manual Sanchez Yanez,
• Gabriel Luna-Bárcenas,
• Samik Chakraborty,
• Sujay Paul and
• Miriam Estevez

Beilstein J. Nanotechnol. 2022, 13, 201–218, doi:10.3762/bjnano.13.15

• dendrimer nps as well as inorganic nanoscale drug carriers are currently used for drug delivery [101]. Almost all of them show higher bioavailability as their uptake mechanism is by absorptive endocytosis, and the slow release of drugs in the blood circulatory system efficiently maintains the level of

Bacterial safety study of the production process of hemoglobin-based oxygen carriers

• Axel Steffen,
• Yu Xiong,
• Radostina Georgieva,
• Ulrich Kalus and
• Hans Bäumler

Beilstein J. Nanotechnol. 2022, 13, 114–126, doi:10.3762/bjnano.13.8

• possible applications for these microparticles. For example, enzyme particles have been produced to be used as microreactors or biosensors [4]. This method can also represent a promising approach to the production of drug carriers by the precipitation of favorable biopolymers and corresponding surface

Biocompatibility and cytotoxicity in vitro of surface-functionalized drug-loaded spinel ferrite nanoparticles

• Sadaf Mushtaq,
• Khuram Shahzad,
• Tariq Saeed,
• Anwar Ul-Hamid,
• Bilal Haider Abbasi,
• Nafees Ahmad,
• Waqas Khalid,
• Muhammad Atif,
• Zulqurnain Ali and
• Rashda Abbasi

Beilstein J. Nanotechnol. 2021, 12, 1339–1364, doi:10.3762/bjnano.12.99

• excellent magnetic, colloidal, cytotoxic, and biocompatible aspects. However, detailed mechanistic, in vivo cytotoxicity, and magnetic-field-assisted studies are required to fully exploit these nanocarriers in therapeutic applications. Keywords: anticancer drugs; doxorubicin; drug carriers; in vitro

pH-driven enhancement of anti-tubercular drug loading on iron oxide nanoparticles for drug delivery in macrophages

• Karishma Berta Cotta,
• Sarika Mehra and
• Rajdip Bandyopadhyaya

Beilstein J. Nanotechnol. 2021, 12, 1127–1139, doi:10.3762/bjnano.12.84

• deployment in drug delivery is contingent upon controlled drug loading and a desired release profile, with simultaneous biocompatibility and cellular targeting. Iron oxide nanoparticles (IONPs), being biocompatible, are used as drug carriers. However, to prevent aggregation of bare IONPs, they are coated

Use of nanosystems to improve the anticancer effects of curcumin

• Andrea M. Araya-Sibaja,
• Norma J. Salazar-López,
• Krissia Wilhelm Romero,
• José R. Vega-Baudrit,
• J. Abraham Domínguez-Avila,
• Carlos A. Velázquez Contreras,
• Ramón E. Robles-Zepeda,
• Mirtha Navarro-Hoyos and
• Gustavo A. González-Aguilar

Beilstein J. Nanotechnol. 2021, 12, 1047–1062, doi:10.3762/bjnano.12.78

• increased pharmacokinetics and anticancer activity when the molecule was co-loaded with resveratrol and gelucire and tested in vitro against human colon cancer HCT-116 cells [68]. Nanostructured lipid carriers (NLC). Nanostructured lipid carriers are the second generation of drug carriers. They are made up

Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications

• Sepand Tehrani Fateh,
• Lida Moradi,
• Elmira Kohan,
• Michael R. Hamblin and
• Amin Shiralizadeh Dezfuli

Beilstein J. Nanotechnol. 2021, 12, 808–862, doi:10.3762/bjnano.12.64

• despite the complexity and a large number of parameters to be optimized [2]. However, despite a large amount of innovations and laboratory researches, the efficacy and safety of nanomaterials used as drug carriers should be evaluated through clinical trials in order to be available in the clinical setting

• considered [30][36]. Many different smart or stimulus-responsive drug carriers have been used in combination with US. These include exosomes, liposomes, polymeric, organic or inorganic hybrid NPs, as well as other nanomaterials to control drug release behavior as well as to investigate their potential

Recent progress in magnetic applications for micro- and nanorobots

• Ke Xu,
• Shuang Xu and
• Fanan Wei

Beilstein J. Nanotechnol. 2021, 12, 744–755, doi:10.3762/bjnano.12.58

• magnetic helices have been shown to be used as drug carriers delivering liposomes loaded with drugs or DNA to single cells [80]. This reflects the prominent role of tubular and helical spermbots and microrobotic for research on medical treatment. Different from the magnetic tubular and helical structures

Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine

• Valentina Francia,
• Daphne Montizaan and
• Anna Salvati

Beilstein J. Nanotechnol. 2020, 11, 338–353, doi:10.3762/bjnano.11.25

• Valentina Francia Daphne Montizaan Anna Salvati Groningen Research Institute of Pharmacy, University of Groningen, 9713AV Groningen, Netherlands 10.3762/bjnano.11.25 Abstract Nano-sized materials have great potential as drug carriers for nanomedicine applications. Thanks to their size, they can

• exploit the cellular machinery to enter cells and be trafficked intracellularly, thus they can be used to overcome some of the cellular barriers to drug delivery. Nano-sized drug carriers of very different properties can be prepared, and their surface can be modified by the addition of targeting moieties

• . Keywords: cell receptors; drug targeting; endocytosis; nanoparticle corona; nanoparticle uptake; Introduction Nano-sized materials are widely studied in nanomedicine for their potential use as drug carriers, in imaging, and for diagnostic purposes [1][2][3]. Because of their size, they can interact with

Fully amino acid-based hydrogel as potential scaffold for cell culturing and drug delivery

• Dávid Juriga,
• Evelin Sipos,
• Orsolya Hegedűs,
• Gábor Varga,
• Miklós Zrínyi,
• Krisztina S. Nagy and
• Angéla Jedlovszky-Hajdú

Beilstein J. Nanotechnol. 2019, 10, 2579–2593, doi:10.3762/bjnano.10.249

• , the applicability of the amino acid-based hydrogels in drug delivery is very important. Therefore, the second aim of our work was to investigate the potential of the scaffolds as drug carriers. To get a better understanding of the fate of the drug in the living system, the release kinetics were

Microfluidics as tool to prepare size-tunable PLGA nanoparticles with high curcumin encapsulation for efficient mucus penetration

• Nashrawan Lababidi,
• Valentin Sigal,
• Aljoscha Koenneke,
• Konrad Schwarzkopf,
• Andreas Manz and
• Marc Schneider

Beilstein J. Nanotechnol. 2019, 10, 2280–2293, doi:10.3762/bjnano.10.220

• , 66119 Saarbrücken, Germany KIST Europe, 66123 Saarbrücken, Germany 10.3762/bjnano.10.220 Abstract Great challenges still remain to develop drug carriers able to penetrate biological barriers (such as the dense mucus in cystic fibrosis) and for the treatment of bacteria residing in biofilms, embedded in

• applied to protect drug carriers from being inactivated by avoiding interaction with mucus [9][10][11]. Nanoparticles (NPs) have shown a tremendous effect in terms of facilitating the diffusion of drugs through biological barriers, for example, through thick mucus in cystic fibrosis [10][12][13][14][15

Mannosylated brush copolymers based on poly(ethylene glycol) and poly(ε-caprolactone) as multivalent lectin-binding nanomaterials

• Stefania Ordanini,
• Wanda Celentano,
• Anna Bernardi and
• Francesco Cellesi

Beilstein J. Nanotechnol. 2019, 10, 2192–2206, doi:10.3762/bjnano.10.212

• aggregates (e.g., micelles and vesicles) above their critical aggregation concentration (CAC). The resulting self-assembled nanoparticles can act as drug carriers and delivery systems, being able to accommodate a hydrophobic drug within their hydrophobic core [22], or chemically bind bioactive agents [23][24

Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity

• Sebastian Pieper,
• Hannah Onafuye,
• Dennis Mulac,
• Jindrich Cinatl Jr.,
• Mark N. Wass,
• Martin Michaelis and
• Klaus Langer

Beilstein J. Nanotechnol. 2019, 10, 2062–2072, doi:10.3762/bjnano.10.201

• , opsonisation, and phagocytosis [12]. In previous studies PLA-, PLGA-, PLA-PEG-, and PLGA-PEG-based nanometre-sized drug carriers loaded with or covalently linked to doxorubicin have been prepared by methods including emulsion diffusion, solvent displacement, micelle formation, and film rehydration followed by

• of nanoparticles decreases with an increase of size [53]. PLGA nanoparticles prepared by solvent displacement at pH 7 displayed the highest drug load. Hence, their superior effects may be explained by an increased drug transport per nanoparticle into cancer cells. Nano-sized drug carriers have been

Synthesis and potent cytotoxic activity of a novel diosgenin derivative and its phytosomes against lung cancer cells

• Liang Xu,
• Dekang Xu,
• Ziying Li,
• Yu Gao and
• Haijun Chen

Beilstein J. Nanotechnol. 2019, 10, 1933–1942, doi:10.3762/bjnano.10.189

• by cholesterol have been substantially investigated as drug carriers for targeting, modulating drug pharmacokinetics, and decreasing drug toxicity [15][16]. Liposomes also can be used as solubilizing media to enhance solubility and bioavailability of insoluble drugs [17]. Di and our prepared